The U.S. Food and Drug Administration (FDA) has granted TikoMed AB’s TM-400Orphan Drug Designation for the mobilization of stem cells prior to stem cell transplantation treatment.
Visionary Pharmaceuticals, Inc., has raised seed round investments from a consortium of angel investors.
Key cells in the hippocampus are formed in the base of the brain late in fetal life and undertake a long journey before reaching their final destination in the center of the brain shortly after birth, according to researchers at the National Institutes of Health.
Researchers at the BioPhotonics Laboratory at the UCLA Henry Samueli School of Engineering and Applied Science have developed a compact, lightweight, and cost-effective optofluidic platform that integrates imaging cytometry and fluorescent microscopy and can be attached to a cell phone
Solentim’s Cell Metric uses non-image based focusing to locate possible colonies by imaging the entire well.
Brooks Automation, Inc. has completed the acquisition of Nexus Biosystems, Inc., a California-based global market leader in life science automated compound and sample management solutions for $79 million.
PerkinElmer, Inc. launched its Clarus SQ 8 Gas Chromatography/Mass Spectrometer. The Clarus SQ 8 provides extreme sensitivity to analyze samples accurately, with an 800:1 signal-to-noise specification.
DNA2.0 announced that the first collection of biological building blocks characterized by the BIOFAB International Open Facility Advancing Biotechnology are now available for use in the design and assembly of genes within DNA2.0’s Gene Designer software.
AstraZeneca PLC reported more or less unchanged profits for the second quarter as it weathered a hit to sales revenue from generic competition. AstraZeneca reported a net profit for the period of $2.11 billion, up 0.3 percent from a year earlier.
Cornerstone Pharmaceuticals, Inc. has published a paper describing the selective inhibition of cancer cell energy metabolism by its lipoate derivative compound, CPI-613.
The FDA is notifying pharmaceutical companies that bioanalytical studies conducted by Cetero Research, Houston, Texas between April 2005 and June 2010 in support of marketing applications may need to be repeated or confirmed.
Sanofi saw its earnings slump 41% in the second quarter from a year earlier as growing competition from generic alternatives ate into sales of its more expensive drugs and offset gains from the recent acquisition of U.S. biotechnology firm Genzyme.
Drugmaker Bristol-Myers Squibb Co. said that its second-quarter profit fell nearly 3 percent due to higher taxes and increased costs for production, marketing and administration. Those were partly offset by a 14 percent jump in sales.
Pharmaceutical and chemical company Bayer AG says strong growth in the crop science division helped second-quarter profits rise more than 40 percent. Bayer reported net profits of €747 million for the period.